The antiatherogenic role of high-density lipoprotein cholesterol

American Journal of Cardiology

Volumn 82, Issue 8 SUPPL. 2, 1998, Pages 13-21

  Kwiterovich Jr , Peter O ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ATHEROGENESIS; CHOLESTEROL BILE LEVEL; CHOLESTEROL TRANSPORT; CLINICAL RESEARCH; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CORONARY RISK; CORRELATION FUNCTION; HEALTH PROGRAM; HUMAN; MORTALITY; PRIORITY JOURNAL; RESTENOSIS; RISK FACTOR; SMOKING CESSATION; WEIGHT REDUCTION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; ANTICHOLESTEREMIC AGENTS; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; ESTERASES; HUMANS; INCIDENCE; LIPOPROTEINS, HDL; LIVER; NIACIN; PHOSPHOLIPASES A; PLATELET ACTIVATING FACTOR; PROGNOSIS; RECEPTORS, LIPOPROTEIN; RISK FACTORS; RNA-BINDING PROTEINS; SURVIVAL RATE;

EID: 0032511903     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00808-X     Document Type: Article

References (60)

1. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995;91:2488-2496.
2. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein-cholesterol levels: the Framingham Study. JAMA 1986;256:2835-2838.
3. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease: the Framingham Study. Ann Epidemiol 1992;2:23-28.
4. Kwiterovich PO Jr. The effect of dietary fat, antioxidants and pro-oxidants on blood lipids and lipoproteins and atherosclerosis. J Am Diet Assoc 1997;97(suppl):S31-S41.
5. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 1995;332:512-521.
6. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
7. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
8. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-1622.
9. Brown G, Fuster V. Impact of management in stabilization of coronary disease. In: Fuster V, ROSS R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. New York: Raven Press, 1996:191-205.
10. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High-density lipoprotein as a protective factor against coronary heart disease. Am J Med 1977;62:707-714.
11. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I: Reduction in incidence of coronary heart disease. JAMA 1984;251:351-364.
12. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-1245.
13. Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
14. Dietschy JM. Theoretical considerations of what regulates low-density lipoprotein and high-density lipoprotein cholesterol. Am J Clin Nutr 1997;65:1581S-1589S.
15. Fielding C, Fielding P. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995;36:211-228.
16. O'Connor PM, Zysow BR, Schoenhaus SA, Ishida BY, Kunitake ST, Naya-Vigne JM, Duchateau PN, Redberg RF, Spencer SJ, Mark S, et al. Prebeta-1 HDL in plasma of normolipidemic individuals: influences of plasma lipoproteins, age and gender. J Lipid Res 1998;39:670-678.
17. Tall AR. An overview of reverse cholesterol transport. Eur Heart J 1998;19:A31-A35.
18. Acton S, Rigotti A, Landschultz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high-density lipoprotein receptor. Science 1996;271:518-520.
19. Krieger M. The "best" of cholesterols, the "worst" of cholesterols: a tale of two receptors. Proc Natl Acad Sci USA 1998;95:4077-4080.
20. Bachorik PS, Virgil DG, Kwiterovich PO Jr. Effect of apoE-free HDL on cholesterol metabolism in cultured pig hepatocytes. J Biol Chem 1987;262:13636-13645.
21. Marotti KR, Castle CK, Boyle TP, Lin AH, Murray W, Melchio GW. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993;364:73-75.
22. Breslow JL. Transgenic mouse models of lipoprotein metabolism and atherosclerosis. Proc Natl Acad Sci USA 1993;90:8314-8318.
23. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A1. Nature 1991;353:265-267.
24. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein A-I transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994;94:899-903.
25. Breslow JL. Familial disorders of high-density lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease, 7th ed, Vol. II. New York: McGraw-Hill, Inc., 1995:2031-2052.
26. Glomset JA, Assmann G, Gjone E, Norum KR. Lecithin: cholesterol acyltransferase deficiency and fish-eye disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease, 7th ed, Vol. II. New York: McGraw-Hill, Inc., 1995:1933-1951.
27. Miida TY, Nakamura K, Inano T, Matsuto T, Yamaguchi T, Tsuda T, Okada M. Prebeta-I high-density lipoprotein increases in coronary artery disease. Clin Chem 1996;42:1992-1995.
28. Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR. Increased coronary heart disease in Japanese-American men with mutations in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996;97:2917-2923.
29. Liao JK. Endothelium and acute coronary syndromes. Clin Chem 1998;44:8:1799-1808.
30. Cannon RO III. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem 1998;44:8:1809-1819.
31. Hessler JR, Roberston AL Jr, Chisolm GM. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979;32:213-229.
32. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990;1044:275-283.
33. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Balente AJ, Berliner JA, Drinkwater DC, Laks H, Fogelman AM. Monocyte transmigration induced by modification of low-density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high-density lipoproteins. J Clin Invest 1991;88:2039-2046.
34. Hayek T, Oiknine J, Dankner G, Brook JG, Aviram M. HDL apolipoprotein A-I attenuates oxidative modification of low-density lipoprotein: studies in transgenic mice. Eur J Clin Chem Clin Biochem 1995;33:721-725.
35. Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM. The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low-density lipoprotein. Trans Am Assoc Physiol 1993;106:44-63.
36. Watson AD, Navab M, Hough GP, Hama SY, La Du BN, Young L, Laks H, Permut LC, Fogelman AM, Berliner JA. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized-low density lipoprotein. J Clin Invest 1995;95:774-782.
37. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoproteins. FEBS Lett 1991;286;152-154.
38. Heinecke JW, Lusis AJ. Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? Am J Hum Genet 1998;62:20-24.
39. Sanghera DK, Aston CE, Saha N, Kamboh M. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998;62:36-44.
40. Saku K, Ahmad M, Glas-Greenwalt P, Kashyap ML. Activation of fibrinolysis by apolipoproteins of high-density lipoproteins in man. Thromb Res 1985;39:1-8.
41. Pearson TA, Bulkley BH, Achuff SC, Kwiterovich PO, Gordis L. The association of low levels of HDL cholesterol and arteriographically defined coronary artery disease. Am J Epidemiol 1979;109:285-295.
42. Miller M, Seidler A, Kwiterovich PO, Pearson TA. Long-term predictors of subsequent cardiovascular events with coronary artery disease and "desirable" levels of plasma total cholesterol. Circulation 1992;86:1165-1170.
43. Shah PK, Amin J. Low high-density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. Circulation 1992;85:1279-1285.
44. Dzavik V, Teo K, Yokoyama S, Modi R, Dinwoodie A, Burton JR, Tymchak WJ, Montague TJ. Effect of serum lipid concentration on restenosis after successful de novo percutaneous transluminal coronary angioplasty in patients with total cholesterol 160 to 240 mg/dL and triglycerides <350 mg/dL. Am J Cardiol 1995;75:936-938.
45. Violaris AG, Melkert R, Serruys PW. Influence of serum cholesterol and cholesterol subfractions on restenosis after successful coronary angioplasty: a quantitative angiographic analysis of 3336 lesions. Circulation 1994;90:2267-2279.
46. Johansson SR, Wilkund O, Karlsson T, Hjalmarson A, Emanuelsson H. Serum lipids and lipoproteins in relation to restenosis after coronary angioplasty. Eur Heart J 1991;12:1020-1028.
47. Roth A, Eshchar Y, Keren G, Sheps D, Kerbel S, Laniado S, Miller HI, Rubinstein A, Frimerman A, Pardesa A, et al. Serum lipids and restenosis after successful percutaneous transluminal coronary angioplasty. Ichilov Magnesium Study Group. Am J Cardiol 1994;73:1154-1158.
48. Tardif J-C, Coté G, Lesperance J, Bourassa M, Lambert J. Doucet S, Bilordeau L, Nattel S, DeGuise P. Prevalence and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997;337:365-372.
49. Bhunia AK, Han H, Snowden A, Chatterjee S. Redox-regulated signaling by lactosylceramide in the proliferation of human aortic smooth muscle cells. J Biol Chem 1997;272:15642-15649.
50. Lavie CJ, Mailander L, Milani RV. Marked benefit with sustained-release niacin therapy in patients with "isolated" very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am J Cardiol 1992;69:1083-1085.
51. Alderman JD, Pasternak RC, Sacks FM, Smith HS, Monrad ES, Grossman W. Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high-density lipoprotein cholesterol and the cholesterol to high-density lipoprotein ratio. Am J Cardiol 1989;64:725-729.
52. Luria MH. Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio. Arch Intern Med 1988;148:2493-2495.
53. Miller M, Bachorik PS, McCrindle BW, Kwiterovich PO Jr. Effect of gemfibrozil in men with primary low high-density lipoprotein cholesterol: a randomized, double-blind, placebo-controlled, crossover study. Am J Med 1993;94:7-12.
54. Hunninghake DB, Mellies MJ, Goldberg AC, Kuo PT, Kostis JB, Schrott HG, Insull W Jr, Pan HY. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia: II. Once-daily versus twice-daily dosing. Atherosclerosis 1990;85:219-227.
55. Jones PH, Farmer JA, Cressman MD, McKenney JM, Wright JT, Proctor JD, Berkson DM, Farnham DJ, Wolfson PM, Colfer HT, et al. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study. Clin Cardiol 1991;14:146-151.
56. Rubenfire M, Maciejko JJ, Blevins RD, Orringer C, Kobylak L, Rosman H, Smith MP, Balun JE, Piot N, Gohlke B, et al. The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. Arch Intern Med 1991;151:2234-2240.
57. Goerdt C, Keith M, Rubins HB. Effects of phenytoin on plasma high-density lipoprotein cholesterol levels in men with low levels of high-density lipoprotein cholesterol. J Clin Pharmacol 1995;35:767-775.
58. Miller M, Burgan RG, Osterlund L, Segrest JP, Garber DW. A prospective, randomized trial of phenytoin in nonepileptic subjects with reduced HDL cholesterol. Arterioscler Thromb Vasc Biol 1995;15:2151-2156.
59. Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997;17:2020-2028.
60. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study. Can J Cardiol 1988;4(suppl):5A-10A.